Does Low Molecular Weight Heparin Cause Less Bleeding?

Duncan P Thomas

doi:10.1055/s-0038-1665426

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1997; 78(06): 1422-1425
DOI: 10.1055/s-0038-1665426

Review Article

Schattauer GmbH Stuttgart

Does Low Molecular Weight Heparin Cause Less Bleeding?

Duncan P Thomas

The Division of Hematology/Oncology, University of North Carolina, School of Medicine, Chapel Hill, NC, USA

› Author Affiliations

Abstract

PDF Download

PDF (1072 kb)

References

References
1 Nurmohamed MT, Rosendaal FR, Büller HR, Dekker E, Hommes DW, Vandenbroucke JP, Briët E. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992; 340: 152-156
2 Schafer AE. Low-molecular-weight heparin – an opportunity for home treatment of venous thrombosis. N Engl J Med 1996; 334: 677-681
3 Kakkar VV. Effectiveness and safety of low molecular weight heparins (LMWH) in the prevention of venous thromboembolism (VTE). Thromb Haemost 1995; 74: 364-368
4 Johnson EA, Kirkwood TBL, Stirling Y, Perez-Requejo JL, Ingram GIC, Bangham DR, Brozovic M. Four heparin preparations: anti-Xa potentiating effect of heparin after subcutaneous injection. Thromb Haemost 1976; 35: 586-591
5 Lancet editorial. Prevention of thrombosis. Lancet 1977; 1: 127-128
6 Salzman EW, Rosenberg RD, Smith MH, Lindon JN, Favreau L. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 1980; 65: 64-73
7 Horne MK, Chao ES. The effect of molecular weight on heparin binding to platelets. Br J Haem 1990; 74: 306-312
8 Thomas DP, Merton RE. A low molecular weight heparin compared with unfractionated heparin. Thromb Res 1982; 28: 343-350
9 Agnelli G, Iorio A, Renga C, Boschetti E, Nenci GG, Ofosu FA, Hirsh J. Prolonged antithrombin activity of low-molecular-weight heparins. Clinical implications for the treatment of thromboembolic diseases. Circulation 1995; 92: 2819-2824
10 Hemker HC, Béguin S. Thrombin generation in plasma: its assessment via the endogenous thrombin potential. Thromb Haemost 1995; 74: 134-138
11 Bendetowicz AV, Béguin S, Caplain H, Hemker HC. Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (enoxaparin) after subcutaenous injection, comparison with unfractionated heparin – a three way cross over study in human volunteers. Thromb Haemost 1994; 71: 305-313
12 Barrowcliffe TW, Johnson EA, Thomas DP. Low molecular weight heparin. John Wiley; Chichester; New York: 1992
13 Young E, Cosmi B, Weitz J, Hirsh J. Comparison of the non-specific binding of unfractionated heparin and low molecular weight heparin (enoxaparin) to plasma proteins. Thromb Haemost 1993; 70: 625-630
14 Barrowcliffe TW, Le Shirley Y. The effect of calcium chloride on anti-Xa activity of heparin and its molecular weight fractions. Thromb Haemost 1989; 62: 950-954
15 Thomas DP, Merton RE, Lewis WE, Barrowcliffe TW. Studies in man and experimental animals of a low molecular weight heparin fraction. Thromb Haemost 1981; 45: 214-218
16 Carter CJ, Kelton JG, Hirsh J, Cerskus A, Santos AV, Gent M. The relationship between the hemorrhagic and antithrombotic coagulant properties of two low molecular weight heparins. Blood 1982; 59: 1239-1245
17 Diness V, Nielsen JI, Pedersen PC, Wolfbrandt KH, Ostergaard PB. The effect of heparin fragments of different molecular weights on experimental thrombosis and haemostasis. Thromb Res 1985; 38: 589-601
18 Pangrazzi J, Abbadini M, Zameta M, Naggi A, Torri G, Casu B, Donati M. Antithrombotic and bleeding effects of a low molecular weight heparin fraction. Biochem Pharmacol 1985; 34: 3305-3308
19 Green D, Hirsh J, Heit J, Prins M, Davidson B, Lensing AWA. Low molecular weight heparin: a critical analysis of clinical trials. Pharmacol Rev 1994; 46: 089-109
20 Schmitz-Huebner U, Bunte H, Freize G, Reers B, Ruschemeyer C, Scherer R, Schulte H, van de LooJ. Clinical efficacy of low molecular weight heparin in postoperative thrombosis prophylaxis. Klinische Wochenschrift 1984; 62: 349-353
21 Koller M, Schoch U, Buchmann P, Largiader F, von Felten A, Frick PG. Low molecular weight heparin (Kabi 2165) as thromboprophylaxis in elective visceral surgery. A randomized double-blind study versus unfractionated heparin. Thromb Haemost 1986; 56: 243-246
22 Turpie AGG, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ, Andrew M, Hull RD, Gent M. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1986; 315: 925-929
23 Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Tomgren S, Wallin G. Low molecular weight heparin once daily compared with conventional low-dose heparin twice daily. A prospective doubleblind multicentre trial on prevention of postoperative thrombosis. Br J Surg 1986; 73: 204-208
24 Caen JP. (A French multicenter trial) A randomized double blind study between low molecular heparin (Kabi 2165) and standard heparin in the prevention of deep vein thrombosis in general surgery. Thromb Haemost 1988; 59: 216-220
25 Encke A, Breddin K. (European Fraxiparine Study Group) Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. Br J Surg 1988; 75: 1058-1063
26 Ockelford PA, Patterson J, Johns AS. A double-blind randomized placebo controlled trial of thromboprophylaxis in major elective general surgery using once daily injections of a low molecular weight heparin fragment (Fragmin). Thromb Haemost 1989; 62: 1046-1049
27 Colwell CW, Spiro TE, Trowbridge AA, Morris BA, Kwaan HC, Blaha JD, Comerota AJ, Skoutakis VA. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. J Bone Joint Surg Am 1994; 76: 03-14
28 Levine MN, Hirsh J, Gent M, Turpie AG, LeClerc J, Powers P, Jay RM, Neemer J. Prevention of deep vein thrombosis after elective hip surgery: a randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med 1991; 114: 545-551
29 Kakkar VV, Cohen AT, Edmonson RA, Phillips MJ, Cooper DJ, Das SK, Maher KT, Sanderson RM, Ward VP, Kakkar S. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet 1993; 341: 259-265
30 Boneu B. An international multicentre study: Clivarin in the prevention of venous thromboembolism in patients undergoing general surgery. Report of the International Clivarin Assessment Group. Blood Coagul Fibrinolysis 1993; 4 (01) 521-522
31 Leizorovicz A, Haugh MC, Chapuis F-R, Samama MM, Boissel J-P. Low molecular weight heparin in prevention of perioperative thrombosis. Br Med J 1992; 305: 913-920
32 Anderson DR, O’Brien BJ, Levine MN, Roberts R, Wells PS, Hirsh J. Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty. Ann Intern Med 1993; 119: 1105-1112
33 Kakkar VV. Efficacy and safety of Clivarin and other LMWH’s in general surgery: a meta-analysis. Blood Coagul Fibrinolysis 1993; 4 (01) 523-527
34 Geerts WH, Jay RM, Code KI, Chen G, Szalai JP, Saibil EA, Hamilton PA. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med 1996; 335: 701-707
35 Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie AG. et al A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334: 677-681
36 Koopman MMW, Prandoni P, Provella F, Ockelford PA, Brandjes PM, van der Meer J, Gallus AS, Simonneau G. et al Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Eng J Med 1996; 334: 682-687
37 Lensing AW, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparin. A meta-analysis. Arch Intern Med 1995; 155: 601-607
38 Hull RD, Raskob MB, Pineo GF, Green D, Trowbridge AA, Elliot G, Lemer RG. et al Subcutaneous low molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis. N Engl J Med 1992; 326: 975-982
39 Hirsh J, Siragusa S, Cosmi B, Ginsberg JS. Low molecular weight heparins (LMWH) in the treatment of patients with acute venous thromboembolism. Thromb Haemost 1995; 74: 360-363
40 Albada J, Nieuwenhuis HK, Sixma JJ. Treatment of acute thromboembolism with low molecular weight heparin (Fragmin). Circulation 1989; 80: 935-940
41 Prandoni P, Lensing AWW, Buller HR, Carta M, Cogo A, Vigo M, Casara D, Ruol A, ten CateJW. Comparison of subcutaneous low molecular weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992; 339: 441-455
42 Leizorovicz A, Simonneau G, Decousus H, Boissel JP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis. Br Med J 1994; 309: 299-304
43 The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997; 337: 657-662
44 Simonneau G, Sors H, Charbonnier B. et al A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997; 337: 663-669
45 Warkentin TE, Levine MN, Hirsh J. et al Heparin-induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-1335